Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Salarius Pharmaceuticals, Inc. SLRX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Salarius Pharmaceuticals, Inc. (SLRX) is a Biotechnology company in the Healthcare sector, currently trading at $0.84. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Net income is $13M (loss), growing at -3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $6M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.13 (strong liquidity). Debt-to-assets is 0%. Total assets: $11M.

Analyst outlook: 1 / 1 analysts rate SLRX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

SLRX SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SLRX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
SLRX: +0%/yr revenue is, -3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SLRX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.13 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
SLRX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate SLRX as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.515-52.95
Volume5.96M
Avg Volume (30D)3.68M
Market Cap$4.92M
Beta (1Y)0.32
Share Statistics
EPS (TTM)-25.99
Shares Outstanding$481.59K
IPO Date2015-01-29
Employees2
CEOFrederick E. Pierce
Financial Highlights & Ratios
Gross Profit$-8.52M
EBITDA$-12.61M
Net Income$-12.52M
Operating Income$-12.61M
Total Cash$10.71M
Net Debt$-10.71M
Total Assets$11.06M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS79400X5032

Price Chart

Track all markets on TradingView
SLRX
Salarius Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.52 52WK RANGE 52.95

People Also View

CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
 MREO
MREO
Mereo BioPharma Group plc
$0.34
+2.98%
 NTRB
NTRB
Nutriband Inc.
$4.08
+0.49%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 SABS
SABS
SAB Biotherapeutics, Inc.
$4.05
+4.92%
 PIRS
PIRS
Pieris Pharmaceuticals, Inc.
$13.60
-15.58%
 AXLA
AXLA
Axcella Health Inc.
$4.58
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message